Collegium Pharmaceuticals – Xtampza Sales Ramp-Up Disappoints – Seeking Alpha


Seeking Alpha
Collegium Pharmaceuticals – Xtampza Sales Ramp-Up Disappoints
Seeking Alpha
Collegium Pharmaceuticals is reporting a slow pick-up in sales for Xtampza, but offers some valid reasons for the slow growth trajectory. The market is not punishing the company as expectations have been low, further growth is anticipated, and
$6.37 Million in Sales Expected for Collegium Pharmaceutical Inc (COLL) This QuarterSports Perspectives
16 hedge funds buy COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) for the first timePost Analyst
Collegium Pharmaceutical Inc (COLL) Issues Quarterly Earnings ResultsThe Cerbat Gem
StreetInsider.com
all 40 news articles >>

Source: pharmaceutical – Google News

Sharing information is key – Pharmaceutical Business News UK. Social Commerce and Social Media Management playing a big part. Suaju Ltd